1. Home
  2. TECX vs SGHT Comparison

TECX vs SGHT Comparison

Compare TECX & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tectonic Therapeutic Inc.

TECX

Tectonic Therapeutic Inc.

HOLD

Current Price

$19.98

Market Cap

366.8M

Sector

N/A

ML Signal

HOLD

Logo Sight Sciences Inc.

SGHT

Sight Sciences Inc.

HOLD

Current Price

$6.25

Market Cap

395.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TECX
SGHT
Founded
2019
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
366.8M
395.5M
IPO Year
2018
2021

Fundamental Metrics

Financial Performance
Metric
TECX
SGHT
Price
$19.98
$6.25
Analyst Decision
Strong Buy
Buy
Analyst Count
5
8
Target Price
$80.40
$8.23
AVG Volume (30 Days)
225.8K
282.4K
Earning Date
03-19-2026
03-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$76,052,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$11.80
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.70
$2.03
52 Week High
$61.07
$9.24

Technical Indicators

Market Signals
Indicator
TECX
SGHT
Relative Strength Index (RSI) 50.53 37.66
Support Level $18.78 $5.95
Resistance Level $20.66 $6.23
Average True Range (ATR) 1.26 0.39
MACD 0.06 -0.05
Stochastic Oscillator 65.50 20.25

Price Performance

Historical Comparison
TECX
SGHT

About TECX Tectonic Therapeutic Inc.

Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.

About SGHT Sight Sciences Inc.

Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.

Share on Social Networks: